FTC Plans to Block $3.5B Covetrus-MWI Deal: What It Means for Cencora and Veterinary Sector Traders

Event Analysis

As reported by Semafor, the U.S. Federal Trade Commission plans to sue to block the $3.5 billion merger between Covetrus — the privately held veterinary software and pharmacy platform owned by Clayton, Dubilier & Rice and TPG — and MWI Animal Health, a subsidiary of Cencora (COR). According to SEC filings, the deal structure would deliver Cencora $1.25 billion in upfront cash, $800 million in preferred equity, and $1.45 billion in common equity, with Cencora retaining a roughly 34.3% non-controlling stake in the combined entity. The FTC's core concern, per sources cited by Semafor, is that the combination would create a highly concentrated national market for veterinary products and services, potentially raising costs for pet owners and clinics.

What makes this significant beyond the headline is the deal's layered structure. This isn't a straightforward cash acquisition — Cencora's exit from animal health was partially deferred through equity stakes rather than a clean cash exit. A blocked deal doesn't just eliminate the $1.25 billion cash payment; it unwinds the entire capital-allocation thesis Cencora built around this transaction. Reuters separately confirmed that the FTC had been examining the merger closely and that Covetrus and MWI had already submitted remedies to regulators, which were rejected. The willingness to push to litigation signals a global regulatory enforcement wave posture rather than a negotiated consent decree.

This fits a broader pattern of heightened antitrust scrutiny in healthcare distribution, where regulators have grown increasingly attentive to consolidation among back-end suppliers that may not face obvious consumer-facing competition pressure. The deal combined MWI's distribution network with Covetrus' practice-management software and pharmacy services — essentially a vertical and horizontal squeeze on veterinary clinics' supply options simultaneously.

What This Means for Traders

The direct trading implication centers on Cencora (COR), currently trading at $349.09, down 0.24% on the session. The stock is effectively pricing in some deal-at-risk premium already, but a formal FTC lawsuit filing — which has not yet occurred as of reporting — would mark a material deterioration in deal certainty. The loss of $1.25 billion in expected cash proceeds, combined with the devaluation of the preferred and common equity consideration, removes a significant near-term capital return catalyst. Traders should watch for confirmation of a formal complaint filing, which would likely trigger a sharper leg lower in COR.

For the broader veterinary and animal-health sector, Zoetis (ZTS) and IDEXX Laboratories (IDXX) represent cross-market read-throughs. A blocked deal that preserves distributor fragmentation could modestly support pricing dynamics for branded pharmaceutical and diagnostics players who benefit from less concentrated distribution intermediaries. Neither name faces direct deal exposure, but competitive landscape changes in distribution can affect contract terms over time.

Merger-arbitrage desks watching this deal should note that the implied probability of completion falls sharply once the FTC signals litigation intent. As detailed in acquisition arbitrage mechanics, the spread between deal terms and trading price widens with regulatory risk — here manifesting in COR's equity consideration rather than a classic target spread. Volatility in COR CFDs could increase as the formal complaint timeline becomes clearer.

Trade Cencora, Inc. on CoinUnited.io

Trade COR with up to 1000x leverage → | Create Free Account

_Availability and maximum leverage depend on product, jurisdiction and account eligibility. Leverage amplifies losses and positions can be liquidated._